(Q28308162)

Annals of Pharmacotherapy

ChEBI release 2020-05-28

Kelly Biastre

1

0 references

Thomas Burnakis

series ordinal

2

0 references

language of work or name

English

0 references

publication date

February 2009

0 references

published in

0 references

volume

43

0 references

issue

2

0 references

page(s)

283-95

0 references

cites work

How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study

1 reference

Management of overactive bladder and urge urinary incontinence in the elderly patient

21 January 2018

1 reference

Estimated economic costs of overactive bladder in the United States

21 January 2018

1 reference

Pathophysiology of overactive bladder

21 January 2018

1 reference

The overactive bladder: Epidemiology and morbidity

21 January 2018

1 reference

Management of overactive bladder

21 January 2018

1 reference

The challenge of overactive bladder therapy: alternative to antimuscarinic agents

21 January 2018

1 reference

Persistence with antimuscarinic therapy in patients with overactive bladder

21 January 2018

1 reference

Pharmacotherapy of the overactive bladder and advances in drug delivery

21 January 2018

1 reference

Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers.

21 January 2018

1 reference

Maximizing anticholinergic therapy for overactive bladder: has the ceiling been reached?

21 January 2018

1 reference

Muscarinic receptor antagonists for overactive bladder

21 January 2018

1 reference

The overactive bladder syndrome: treating patients on an individual basis

21 January 2018

1 reference

Multicenter phase III trial studying trospium chloride in patients with overactive bladder

21 January 2018

1 reference

Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system

21 January 2018

1 reference

Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study

21 January 2018

1 reference

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

21 January 2018

1 reference

Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials

21 January 2018

1 reference

Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder

21 January 2018

1 reference

Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients

21 January 2018

1 reference

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

21 January 2018

1 reference

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

21 January 2018

1 reference

Darifenacin: Pharmacology and clinical usage

21 January 2018

1 reference

21 January 2018

1 reference

Pharmacologic management of overactive bladder: practical options for the primary care physician

21 January 2018

1 reference

Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder

21 January 2018

1 reference

Clinical pharmacokinetics of trospium chloride

21 January 2018

1 reference

Trospium chloride for the treatment of overactive bladder with urge incontinence.

21 January 2018

1 reference

Trospium chloride: Distinct among other anticholinergic agents available for the treatment of overactive bladder

21 January 2018

1 reference

Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways

21 January 2018

1 reference

Time to onset of improvement in symptoms of overactive bladder using antimuscarinic treatment

21 January 2018

1 reference

Trospium chloride: an update on a quaternary anticholinergic for treatment of urge urinary incontinence

21 January 2018

1 reference

A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials

21 January 2018

1 reference

Overactive bladder pharmacotherapy: what does the future hold?

21 January 2018

1 reference

Overactive bladder in the elderly: a guide to pharmacological management

21 January 2018

1 reference

Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1L160

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

19193592

1 reference

Consolidated OpenCitations Corpus – April 2017